Related Experiment Videos
Adhesive and invasive features in gliomas
1Division of Neuropathology, Medical Center, Johannes Gutenberg University, Mainz, Germany. tews@mail.Uni-Mainz.de
Pathology, Research and Practice
|November 22, 2000
Summary
Glioma invasion involves cell adhesion and matrix degradation. Invasive glioma cells express specific enzymes like cathepsin D, MMP-2, and MMP-9, suggesting therapeutic targets for anti-invasive treatments.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Cancer Research
Background:
- Glioma cell invasion is a complex process involving cell adhesion, extracellular matrix degradation, and migration.
- Understanding the molecular factors that mediate glioma invasion is crucial for developing effective anti-invasive therapies.
Purpose of the Study:
- To identify factors involved in glioma cell invasion in situ.
- To investigate the expression of specific proteins and enzymes in different glioma types and their correlation with invasion.
Main Methods:
- Immunohistochemical analysis of 45 gliomas (astrocytomas, glioblastomas, oligodendrogliomas, mixed gliomas).
- Assessed expression of CD44s, laminin, collagen IV, fibronectin, galectin-3, tenascin, N-CAM, matrix metalloproteinases (MMP-2, MMP-9), and cathepsin D.
- Correlated protein expression with tumor cell adhesion, invasion, and migration patterns.
Main Results:
- Tumor cells showed strong expression of CD44s, tenascin, galectin-3, and N-CAM in solid tumor masses, suggesting a role in cell adhesion.
- Single invading cells exhibited distinct expression of MMP-2, MMP-9, and cathepsin D, indicating their involvement in matrix degradation and invasion.
- These degrading enzymes were also found in solid tumor areas, facilitating the invasion of single neoplastic cells.
Conclusions:
- Glioma invasion is characterized by a shift in protein expression from adhesion molecules (CD44s, galectin-3, tenascin, N-CAM) in solid tumors to matrix-degrading enzymes (cathepsin D, MMP-2, MMP-9) in invasive cells.
- Targeting these specific factors, particularly the matrix-degrading enzymes, may offer a potential strategy for anti-invasive therapy in gliomas.